European Commission logo
English English
CORDIS - EU research results
CORDIS

MOXO-Mobile: the first Attention Deficit Hyperactive Disorder (ADHD) screening mobile application, using Eye Tracking and Continuous Performance Test components to give the first evidence of attention

Project description

New mobile app to test for ADHD

Attention deficit hyperactivity disorder (ADHD) is a common behavioural disorder that can affect children and teens and includes symptoms such as inattentiveness, hyperactivity and impulsiveness. If untreated, it can lead to difficulties in school and high rates of dropout, substance or alcohol abuse and delinquency. It affects more than 26 million Europeans. However, early detection and treatment can dramatically reduce the symptoms. The EU-funded MOXO-Mobile Phase-1 project will bring to market the MOXO-Mobile – the first ADHD-screening smartphone application. Based on continuous performance test (CPT) and eye tracking (ET), the MOXO-Mobile allows all smartphone owners to test possible attentional dysfunctions and offers guidance for further diagnosis.

Objective

Undiagnosed ADHD leads to learning and social difficulties, school drop-out, unemployment, criminality, and even premature death.

Early diagnosis can dramatically improve the quality of life of at least 26 million individuals in the EU, prevent incarceration and recidivism, and save lives.

MOXO-Mobile is the first ADHD screening mobile application, combining a Continuous Performance Test (CPT) and Eye Tracking (ET) to give an accurate and simple evaluation of the evidence of attentional difficulties. Using this application, every smartphone user could assess his/her attention level and profile and receive further guidance, in case of need, for further diagnosis.

The application will be downloaded for free with pay-per-use strategy as the user will purchase tests as he wishes for himself and his family.

MOXO-Mobile will create a new market (ADHD screening), with max market potential of €2.8B and a projected ROI of 6.1 in 3 years for MOXO-Mobile.

SMEi Phase 1 will enable Neurotech-Solutions to conduct a wide feasibility study, establish an elaborated business plan, risk
assessment, and a sustainability estimation of the product.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

NEURO TECHNOLOGY SOLUTIONS LTD
Net EU contribution
€ 50 000,00
Address
HAPLADA 3
6021803 OR YEHUDA
Israel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00